AVITA Medical, Inc. (RCEL) Reports In-Line Q4 EPS ; Offers Guidance

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q4 EPS of ($0.38), in-line with the analyst estimate of ($0.38). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $17.52 million.

GUIDANCE:

AVITA Medical, Inc. sees FY2026 revenue of $80-85 million, versus the consensus of $124.2 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Applied Optoelectronics sets up $600M at-the-market stock offering
• Aptevo Therapeutics files prospectus for resale of 6.4M shares